Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis

Gut

Volumn 50, Issue 2, 2002, Pages 241-247

  Raetsch, C ^b   Jia, J D ^a,b   Boigk, G ^b   Bauer, M ^a   Hahn, E G ^a   Riecken, E O ^b   Schuppan, D ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; CYTOKINE; MESSENGER RNA; PENTOXIFYLLINE; PROCOLLAGEN; PROCOLLAGEN III N PEPTIDE; PROCOLLAGEN TYPE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; BILE DUCT OBSTRUCTION; BILIARY CIRRHOSIS; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FIBROGENESIS; LIVER FIBROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SCORING SYSTEM;

EID: 0036155891     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.50.2.241     Document Type: Article

References (64)

1. Hepatic fibrosis - Therapeutic strategies
2. Elevated serum aminoterminal procollagen type-III-peptide parallels collagen accumulation in rats with secondary biliary fibrosis
3. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats
4. An oral endothelin A receptor antagonist blocks collagen synthesis and deposition in advanced rat secondary biliary fibrosis
5. Experimental models of hepatic fibrosis: An overview
6. Suppression of experimental hepatic fibrosis by administration of vitamin A
7. Vitamin E dietary supplementation inhibits transforming growth factor beta 1 gene expression in the rat liver
8. Pentoxifylline - A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy
9. Effects of pentifylline on blood hyperviscosity and peripheral hemodynamics in patients with peripheral obliterating arterial disease
10. 198Au-colloid-scintigraphy
11. Effect of pentoxifylline on liver plasma flow in normal man
12. Influence of pentoxifylline and albifylline on liver microcirculation and leucocyte adhaesion after haemorrhagic shock in the rat
13. Inhibitors and activators of cyclic nucleotide phosphodiesterase
14. Pentoxifylline inhibits normal human dermal fibroblast in vitro proliferation, collagen, glycosaminoglycan, and fibronectin production, and increases collagenase activity
15. Pentoxifylline inhibits the proliferation of human fibroblasts derived from keloid, scleroderma and morphoe skin and their production of collagen, glycosaminoglycans and fibronectin
16. Pentoxifylline inhibits the proliferation and glycosaminoglycan synthesis of cultured fibroblasts derived from patients with Graves' ophthalmopathy and pretibial myxoedema
17. Pentoxifylline, pentifylline, and interferons decrease type I and type procollagen mRNA levels in dermal fibroblasts: Evidence for mediation by nuclear factor 1 down-regulation
18. The cell biology of liver fibrogenesis - An imbalance of proliferation, growth arrest and apoptosis of myofibroblasts
19. The cellular basis of hepatic fibrosis
20. Molecular regulation of hepatic fibrogenesis
21. Effect of pentoxifylline on the fibrogenic functions of cultured rat liver fat-storing cells and myofibroblasts
22. Inhibition by pentoxifylline of extracellular signal-regulated kinase activation by platelet-derived growth factor in hepatic stellate cells
23. Pentoxifylline inhibits growth and collagen synthesis of cultured human hepatic myofibroblast-like cells
24. Effect of pentoxifylline on the degradation of procollagen type I produced by hepatic stellate cells in response to transforming growth factor-beta 1
25. Pentoxifylline prevents fibrosis in an animal model and inhibits platelet-derived growth factor-driven proliferation of fibroblasts
26. Expression of connective tissue growth factor in experimental rat and human liver fibrosis
27. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis
28. The integrated value of serum procollagen III peptide over time predicts hepatic hydroxyproline content and stainable collagen in a model of dietary cirrhosis in the rat
29. A simple method to determine nanogram levels of hydroxyproline in biological tissues
30. Serum concentration of the aminoterminal procollagen type III peptide in the rat reflects early formation of connective tissue in experimental liver cirrhosis
31. Construction of DNA sequences complementary to rat alpha 1 and alpha 2 collagen mRNA and their use in studying the regulation of type I collagen synthesis by 1,25-dihydroxyvitamin D
32. Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs: Genomic complexity and molecular evolution of the gene
33. cDNA cloning by PCR of rat transforming growth factor beta-1
34. Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis
35. Structure, mapping, and expression of fisp-12, a growth factor-inducible gene encoding a secreted cysteine-rich protein
36. Identification of a gene family regulated by transforming growth factor-beta
37. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
38. Pentoxifylline prevents liver fibrosis but induces cellular damage in carbon tetrachloride injured rats
39. Effect of pentoxifylline on early proliferation and phenotypic modulation of fibrogenic cells in two rat models of liver fibrosis and on cultured hepatic stellate cells
40. Effects of simvastatin, pentoxifylline and spironolaclone on hepatic fibrosis and portal hypertension in rats with bile duct ligation
41. Effects of pentoxifylline, pentifylline and gamma-interferon on proliferation, differentiation, and matrix production of human renal fibroblasts
42. Synthesis of tissue inhibitor of metalloproteinase-1 (TIMP-1) in human hepatoma cells: Upregulation by interleukin-6 and transforming growth factor β1
43. Tissue inhibitor of metalloproteinase-1 and -2 RNA expression in rat and human liver fibrosis
44. Effects of two methylxanthines, pentoxifylline and propentofylline, on arachidonic acid metabolism in platelets stimulated by thrombin
45. Proliferation and phenotypic modulation of portal fibroblasts in the early stages of cholestatic fibrosis in the rat
46. Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: Down-regulation by cAMP
47. Effect of cyclic AMP on the intracellular degradation of newly synthesized collagen
48. Regulatory elements in the 5′-flanking region of and the first intron contribute to translational control of the mouse alpha 1 type I collagen gene
49. A nuclear factor 1 binding site mediates the transcriptional activation of a type I collagen promoter by transforming growth factor-β
50. Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells
51. Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3′,5′-monophosphate
52. Cellular and molecular regulation of tumor necrosis factor-alfa production by pentoxifylline
53. Pentoxifylline inhibits production of superoxide anion and tumor necrosis factor by Kupffer cells in rat liver preservation
54. Cyclic 3′,5′-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney
55. Pentoxifylline in the treatment of HIV infection and its complications
56. Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis
57. A major role of matrix metalloproteinases in T cell injury in the gut
58. Pentoxifylline blocks hepatic stellate cell activation independently of phosphopdiesterase inhibitory activity
59. Inhibition of collagen lattice contraction by pentoxifylline and interferon-alpha, -beta and -gamma
60. Chemotherapeutic potential of phosphodiesterase inhibibitors
61. Inhibition by xanthine derivaties of adenosine receptor-stimulated cyclic adenosine 3′,5′-monophosphate accumulation in rat and guinea pig thymocytes
62. Differential regulation of human monocyte-derived TNF-alfa and IL-1 beta by type IV cAMP phosphodiesterase (cAMP-PDE) inhibitors
63. Successful targeting to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen type VI receptor
64. Serum assays for liver fibrosis